Lantern Pharma shares AI tools rare cancer presentation

Lantern Pharma Inc. filed a current report describing an investor and stakeholder event held on January 22, 2026.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Lantern Pharma Inc. filed a current report describing an investor and stakeholder event held on January 22, 2026. During this event, the company used a presentation to support discussions and a live demonstration of its initial artificial intelligence tools and multi-agent system that are being developed to focus on rare cancers. The same presentation is furnished as Exhibit 99.1 to the report and is not treated as formally filed financial information. This update is intended to share information under Regulation FD, giving the market equal access to the materials used at the event.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lantern Pharma Inc. (LTRN) disclose in this 8-K?

Lantern Pharma Inc. furnished a presentation used at a January 22, 2026 event where it discussed and demonstrated its initial AI tools and multi-agentic system focused on rare cancers.

What is the focus of Lantern Pharma Inc.'s AI tools mentioned in the 8-K?

The AI tools and multi-agentic system described are focused on rare cancers, and were demonstrated live during the January 22, 2026 company-hosted event.

How is the Lantern Pharma (LTRN) presentation treated for SEC purposes?

The presentation in Exhibit 99.1 is furnished under Item 7.01 Regulation FD Disclosure and is not deemed filed for purposes of Section 18 of the Exchange Act.

Where can investors find the AI presentation Lantern Pharma used at the January 22, 2026 event?

The presentation is included as Exhibit 99.1 to the current report and is incorporated into the disclosure by reference under Item 7.01.

Does this Lantern Pharma 8-K include financial statements or earnings data?

No. The report focuses on furnishing a presentation related to AI tools and a multi-agentic system for rare cancers and does not include financial statements or earnings data.

What exhibits are included with Lantern Pharma Inc.'s January 22, 2026 8-K?

The exhibits are 99.1, a presentation relating to the January 22, 2026 event on AI tools and a multi-agentic system for rare cancers, and 104, the cover page interactive data file in Inline XBRL format.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 01/23/2026 - 07:31 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 22, 2026

Lantern Pharma Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39318

46-3973463

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1920 McKinney Avenue, 7th Floor

Dallas, Texas

75201

(Address of Principal Executive Offices)

(Zip Code)

(972) 277-1136

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: Common Stock

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value		LTRN		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 22, 2026, the Company utilized a presentation to assist with the Company’s discussions during an event hosted by the Company to discuss and demonstrate in a live environment the initial AI tools and multi-agentic system developed by the Company and focused on rare cancers. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Exhibit Description

99.1		Presentation relating to January 22, 2026 event hosted by the Company to discuss and demonstrate the initial AI tools and multi-agentic system developed by the Company and focused on rare cancers.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Lantern Pharma Inc.,
	A Delaware Corporation

Dated: January 22, 2026	By:	/s/ David R. Margrave
		David R. Margrave, Chief Financial Officer

Source: View Original Filing on SEC EDGAR